Clinical Trials · NCT00505882

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

WithdrawnPhase 4Pramlintide (Prohibited)
Phase
Phase 4
Recruitment status
Withdrawn
Sponsor
University of Texas Southwestern Medical Center
Enrollment
0
Start date
Jul 2007
Locations
1 site, United States
Primary endpoint
The change in weight (kg) will be compared between as well as within the placebo and the pramlintide treatment group from baseline to the end of the study.
View Pramlintide compound reference